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Abstract (375 words) 
Importance: The established chronic kidney disease (CKD) progression endpoint, end-stage renal disease 
(ESRD) or doubling of serum creatinine (corresponding to a change in estimated glomerular filtration 
rate (eGFR) of -57% or greater) is a late event, limiting feasibility of nephrology clinical trials. 
Objective: To characterize the association of decline in eGFR with subsequent progression to ESRD, with 
implications for using lesser declines in eGFR as potential alternative endpoints for CKD progression. 
Since most people with CKD die before reaching ESRD, we also investigated mortality risk. 
Data Sources: Individual meta-analysis of up to 1.7 million participants with 12,344 ESRD events and  
223,944 deaths from 35 cohorts. 
Study Selection: Cohorts in the CKD Prognosis Consortium with a repeated measure of serum creatinine 
over 1-3 years and outcome data.  
Data Extraction and Synthesis: Transfer of individual participant data or standardized analysis of 
outputs for random effects meta-analysis took place between July 2012 and September 2013 with 
baseline eGFRs during 1975-2011.  
Main Outcomes and Measures: ESRD (initiation of dialysis or transplantation) or all-cause mortality risk 
related to percent change in eGFR over 2 years adjusted for potential confounders and first eGFR.  
Results: The adjusted hazard ratios (HR) of ESRD and mortality were exponentially higher with larger 
eGFR decline. Among participants with baseline eGFR <60 ml/min/1.73m2, the adjusted HRs for ESRD 
were 32 (95% CI 22-46) and 5.4 (4.65-6.4) for -57% and -30% eGFR changes, respectively.  However, 
changes of -30% or greater were much more common than changes of -57% (6.9% (6.4-7.4%) vs. 0.79% 
(0.5752-1.0006%) in the whole consortium). This association was strong and consistent across length of 
baseline (1 or 3 years), baseline eGFR, age, diabetes status, or albuminuria. Average adjusted 10-year 
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risk of ESRD for eGFR changes of -57%, -40%, -30% and 0% were 99% (95-100%), 8483% (71-93%), 
6564% (5352-77%), vs. 18% (15-22%) respectively at baseline eGFR of 35 ml/min/1.73m2. Corresponding 
mortality risks were 77% (7271-82%), 60% (5756-63%), 50% (4847-5352%), vs. 32% (31-33%), showing a 
similar but weaker pattern. 
Conclusions and Relevance: Declines in eGFR smaller than doubling of serum creatinine occur more 
commonly and are strongly and consistently associated with the risk of ESRD and mortality, supporting 
consideration of lesser declines in eGFR, such as 30% reduction over 2 years, as an alternative endpoint 
for CKD progression.  
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Background 
Chronic kidney disease (CKD) is a world-wide public health problem, with increasing prevalence, poor 
outcomes and high cost.1  Yet, despite the availability of simple laboratory tests to identify people with 
earlier stages of CKD, there are fewer clinical trials for kidney disease than for other common diseases.2  
One contributing reason may be that the established endpoint used to document CKD progression, 
namely, a doubling of serum creatinine from baseline (corresponding to a 57% reduction in estimated 
glomerular filtration rate (eGFR)), is a late event, requiring long follow-up periods and large sample 
sizes.2-4  Improved methods for GFR estimation may allow for use of smaller reductions in eGFR than 
doubling of serum creatinine as alternative endpoints to assess CKD progression.4,5  Evaluation of such 
alternative endpoints should include their enumeration and quantification of their relationship to future 
progression to end-stage renal disease (ESRD) across a wide range of settings.   Standardized definitions 
of CKD progression outcomes would also benefit observational studies and clinical practice. 
 
One-year change in estimated GFR was strongly related to risk of ESRD in the Alberta Kidney Disease 
Network (AKDN).6  Other studies focused on mortality and cardiovascular disease since these outcomes 
occur more commonly than ESRD and showed a strong relationship with various definitions for CKD 
progression.7-11  A systematic evaluation across studies using a uniform analytic approach is needed to 
provide a more rigorous basis for determining the prognosis associated with specific declines in eGFR.   
Clinical trials with doubling of serum creatinine or ESRD as an end-point typically have follow-up of 
approximately 5 years.  The goal for alternative kidney endpoints is to enable clinical trials of shorter 
duration, with 2-years thought to be useful for observing a meaningful change in eGFR, but the 
prognostic implications of shorter and longer periods for observing eGFR change need to be quantified 
as well.   A rigorous evaluation of estimates of CKD progression is also important to inform observational 
studies and clinical practice where various measures of CKD progression have been used.7 
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 We examined the prognostic contribution of change in eGFR over 1, 2 and 3 years to subsequent ESRD 
and mortality in a large international consortium to test its strength and consistency across subgroups 
defined by baseline kidney function and comorbid conditions and provide the evidence base for 
evaluating the usefulness of potential alternative endpoints for CKD progression.   
 
Methods 
Study selection criteria 
Details of the Chronic Kidney Disease Prognosis Consortium (CKD-PC) are described elsewhere and in 
eAppendices 1-2.12-16 Briefly, CKD-PC consists of 50 cohorts with at least 1,000 participants (not applied 
to cohorts predominantly enrolling persons with CKD [CKD cohorts]) with data on serum creatinine and 
albuminuria and 50 or more events of outcomes of interest (either mortality or kidney outcome).12-16 All 
cohorts with appropriate data opted into this study, which included 22 cohorts (4 general population 
cohorts, 5 high-risk cohorts in terms of cardiovascular risk, and 13 CKD cohorts) with a repeated 
measure of serum creatinine during an elapsed period of 0.5-3.5 years to determine the relationship of 
change in eGFR on subsequent ESRD; 35 cohorts (15 general population cohorts, 7 high-risk cohorts in 
terms of cardiovascular risk, and 13 CKD cohorts) included mortality outcomes. Each meta-analysis for 
the present study was restricted to cohorts with at least 10 events and participants aged ≥18 years. Data 
transfer and analysis took place between July 2012 and September 2013. This study was approved by 
the institutional review board for use of de-identified data at the Johns Hopkins Bloomberg School of 
Public Health (Baltimore, Maryland, USA). 
 
Procedures 
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eGFR was calculated using the CKD-EPI 2009 creatinine equation.4,16 In cohorts where the creatinine 
measurement was not standardized to isotope dilution mass spectrometry (IDMS), creatinine 
concentrations were reduced by 5%, the established calibration factor, and drift over time was 
corrected when possible.17  
 
We tested two indices of change in eGFR during a baseline period, percent change and slope (annual 
change in eGFR). Percent change in eGFR was calculated as follows: (last eGFR – first eGFR)/(first eGFR) 
* 100%. The slope was determined as an annual change estimated from a least-square regression model 
using all eGFR measurements in the baseline period. As the implications for the magnitude of change in 
eGFR may vary depending on the time for the change, we defined three baseline periods (1, 2, and 3 
years) to determine the change in eGFR and repeated the analysis for each baseline period. The length 
of the baseline periods correspond to the median length of follow-up in a trial which would use change 
in eGFR as an endpoint, also corresponding to periods over which clinicians would want to determine if 
CKD has progressed.  For each baseline period, a 0.5 year of margin before and after the end of the 
period was allowed for determining the last available eGFR to calculate the change (e.g., eGFR between 
0.5 and 1.5 years after the first available eGFR could be used for the 1 year baseline period analysis), but 
the eGFR closest to the end of the period of interest was selected for each participant. Given that 
doubling of serum creatinine, the established kidney endpoint, corresponds to a -57% change in eGFR 
with the CKD-EPI equation (for serum creatinine ≥0.9 mg/dl in men and ≥0.7 mg/dl in women), our 
primary data presentation was based on percent change in eGFR. All covariates were assessed at the 
time of first eGFR (eAppendix 2 shows details for specific cohorts).  
 
We defined diabetes as fasting glucose ≥7.0 mmol/L (126 mg/dl), non-fasting glucose ≥11.1 mmol/L (200 
mg/dl), hemoglobin A1c ≥6.5%, use of glucose lowering drugs, or self-reported diabetes. Participants 
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with a history of myocardial infarction, coronary revascularization, heart failure, or stroke were 
considered to have a history of cardiovascular disease (CVD). As albuminuria was not necessarily 
measured prior to the first available eGFR in several cohorts, adjustment for albuminuria when available 
was conducted only in sensitivity analyses. While the urine albumin-to-creatinine ratio was our primary 
measure of albuminuria, we also included studies with urine albumin excretion rate, urine protein-to-
creatinine ratio (PCR), or quantitative dipstick protein.18  
 
The primary outcome of interest was ESRD after the baseline period. We defined ESRD as initiation of 
renal replacement therapy or death due to kidney disease other than acute kidney injury. ESRD cases 
before baseline period were excluded from the relevant analyses. Since the majority of patients with 
CKD die without reaching ESRD, we repeated the analysis for all-cause mortality as well as 
cardiovascular mortality and non- cardiovascular mortality. Cardiovascular mortality was defined as 
death due to myocardial infarction, heart failure, stroke, or sudden cardiac death. 
 
 
Statistical analysis 
We applied a two-stage analytic approach, whereby each study was first analyzed separately, followed 
by a random-effects meta-analysis. The analysis overview and analytic notes for individual studies are 
described in eAppendix 2. We imputed missing values of covariates but not the main exposure, change 
in eGFR, using cohort-specific mean values (see Appendix 2 for details). We quantified heterogeneity 
with the I2 statistic and χ2 test12 and explored sources of heterogeneity with random-effects meta-
regression analysis. Since the absolute risk of ESRD and the implication of change in eGFR vary 
substantially depending on baseline eGFR, analyses were done stratified by first eGFR with lower eGFR 
defined as less than 60 ml/min/1.73m2 and higher eGFR defined as ≥60 ml/min/1.73m2.  Analyses were 
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performed using Stata/SE 12 software (www.stata.com). We considered 2-sided P-values < 0.05 
statistically significant. 
 
We modeled the adjusted hazard ratios (HRs) of ESRD and mortality after the end of the baseline period 
as a spline function of percent change in eGFR with the aforementioned covariates. In each study, we fit 
piece-wise linear splines for percent change in eGFR (knots were placed at -57%, -25%, -10%, 10%, 25%) 
and 0% change as a reference point. Cox models were adjusted for age, sex, race/ethnicity (blacks vs. 
non-blacks), systolic blood pressure, total cholesterol, diabetes, history of CVD, and first eGFR. Potential 
effect modifiers with change in eGFR were assessed by incorporating interaction terms.  
 
We illustrate the opposite effects of decreasing risk and increasing prevalence of smaller percent 
changes in eGFR using an approximation of the percent population attributable risk (%PAR) calculated 
from the prevalence of percent change in eGFR, using the overall population distributions as a fixed 
standard, and its adjusted HR and 95% confidence interval. It is best to view the calculated %PAR as an 
approximation of the overall percentage of ESRD or mortality risk explained, rather than a truly 
preventable fraction, since change in eGFR is not fully reversible.19 At the range of eGFR change with 
lower risk compared to the reference point, 0% change, %PAR has a negative value corresponding to 
reduced, rather than excess, risk in the population explained by this eGFR change.   
 
We translated meta-analyzed adjusted HRs for percent change in eGFR to absolute risk of ESRD or 
mortality at 1, 3, 5, and 10 years after the baseline period using the weighted average baseline risk. One-
year baseline risk in each cohort was calculated for the following combination of covariates: 60 year old, 
non-black, male, no change in eGFR, a first eGFR of 50 ml/min/1.73m2, a systolic blood pressure of 130 
mm Hg, a total cholesterol of 5 mmol/L, no history of diabetes or CVD.  Risk was scaled for longer follow-
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up and pooled across cohorts using a weighted average (eAppendix 2, implications of lower and higher 
baseline risk were also calculated). We applied the adjusted sub-HRs from competing risk models 
accounting for death as a competing endpoint.20 
 
 
Results 
Study characteristics 
Twenty two cohorts provided data on change in eGFR for a baseline period of 1-year in 1,530,648 
participants who had 12,344 ESRD events during a mean follow-up period of 3.1 years subsequently. For 
baseline periods of 2- and 3-years, the studies included 1,341,193 participants with 8,532 subsequent 
ESRD events and 1,080,274 with 5,159 subsequent ESRD events respectively (Table 1).  Mortality 
analysis included 35 cohorts (1,757,886 participants with 223,944 deaths from 27 cohorts for 1-year, 
1,589,257 participants with 158,603 deaths from 32 cohorts for 2-year, and 1,259,477 participants with 
102,491 deaths from 34 cohorts for 3-year). Baseline assessments in each cohort took place between 
1975-2011, with generally longer follow-up in older cohorts than newer cohorts. The results focus on 
the 2-year baseline period with details for the 1-year and 3-year period provided in supplementary 
appendices.  Participating cohorts spanned a wide spectrum of sample size and baseline characteristics 
(Table 1 and 2 and eTable 1).  The cohort averages for lower and higher eGFR strata were: first eGFR 48 
and 92 ml/min/1.73m2, age 74 and 51 years, female sex 20% and 51%, black race 7% and 1%, diabetes 
38% and 14% and history of CVD 35% and 6%, respectively. 
 
ESRD risk according to change in eGFR 
Overall, change in eGFR over 2 years had a median (5th-95th percentile) of -1% (-26% to +26%), with a 
distribution skewed towards negative values indicating more prevalent eGFR decline (Figure 1). The 
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prevalence of -57% change in GFR was much lower than for lesser changes. Fifty-two percent of ESRD 
cases had a -30% change in eGFR over 2 years whereas only 1516% of ESRD cases reached -57% eGFR 
change in this time frame. Subsequent risk of ESRD showed exponentially higher adjusted HRs at greater 
negative percent changes in eGFR and lower HRs at greater positive percent changes in eGFR compared 
to no change in eGFR, with similar associations for lower and higher eGFR strata (Figure 1 panels A and 
B).  A -57% change in eGFR was associated with an adjusted HRs of ESRD of 32.1 (95% CI 22.3-46.3) and 
57.2 (21.9-149.1) at lower and higher eGFR respectively.  A -30% change in eGFR was associated with an 
adjusted HR of ESRD of 5.4 (95% CI 4.65-6.4) and 6.7 (3.9-11.5) at lower and higher eGFR, respectively. 
Sensitivity analyses assessing the percentage change in eGFR over shorter (1 year) and longer (3 year) 
baseline periods yielded similar associations with ESRD in both the lower and higher GFR strata (Table 3 
and eFigures 1-2). Further adjustment for albuminuria yielded similar results (eFigure 3), as did multiple 
imputation of missing data (eAppendix 2).   
 
The %PAR of ESRD was positive for those with decline in eGFR and negative for those with a rise in eGFR 
compared to those with a stable eGFR (Figure 1).  The %PAR showed that lower risk associated with 
smaller reductions in eGFR were offset by a higher prevalence leading the %PAR to peak around -40% to 
-30% and -30% to -20% for the lower and higher eGFR strata, respectively.  In the lower eGFR stratum 
with a 2-year baseline the cumulative prevalence for eGFR changes of -57% or greater vs. -30% or 
greater was 0.79% (0.5752-1.0006%) and 6.9% (6.4-7.4%), respectively (Table 3). As a result, the 
cumulative %PAR rose markedly from 10% to 44%, respectively.  Thus, of the 63% of ESRD attributable 
to eGFR decline (below 0%), 16% can be attributed to the participants with eGFR change of -57% or 
greater compared to 70% with eGFR change of -30% or greater.  Similar results were observed in the 
higher eGFR stratum. As expected, the cumulative prevalence of any given decline in eGFR and the 
cumulative %PAR were lower during shorter baseline periods and higher during longer baseline periods.     
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 The strength of associations of percent eGFR decline with ESRD was consistent at lower eGFR (19 
studies) and higher eGFR (9 studies) (eFigure 4).  Variation in HRs across studies was not related to 
variation in study characteristics. For example, the adjusted HR of ESRD associated with a -30% change 
in eGFR during 2-years was unrelated to baseline eGFR, prevalence of diabetes and median albuminuria 
(eFigures 5-6), despite each being a strong risk factor for ESRD. Meta-regression of these factors as well 
as mean follow-up time and age across three different baseline periods and two eGFR strata showed no 
pattern (only 4 of 30 combinations with p-values<0.05, eFigures 5-10). 
 
The average absolute risk of ESRD was very strongly related to the first eGFR as well as to the length of 
follow-up and the change in eGFR (Table 4 and eTables 2-3).  For example, at a baseline eGFR of 35 
ml/min/1.73m2 the average 10-year risks of ESRD after a 2-year baseline period during which eGFR 
changed by -57%, -30% and 0% were 99%, 6564%, and 18% respectively, adjusted for covariates and 
competing mortality risk.  While greater decline in eGFR was always associated with a higher subsequent 
risk of ESRD, the absolute and attributable risk varied markedly across patient characteristics, as well as 
across cohorts even after adjustment for covariates (eFigures 11-12 and eTables 2-3).   
 
Analysis of change in eGFR using slope rather than percent change showed strong association with ESRD 
risk as well (eFigures 13-15).  In addition, longer follow-up narrowed the distribution of slopes and 
strengthened the association with ESRD.   
 
Mortality risk according to change in eGFR 
In cohorts with mortality data, again, approximately ten-fold more individuals had an eGFR change of -
30% or greater compared to a -57% change or greater (cumulative prevalence of 7.1% (95% CI 6.6-7.7%) 
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vs. 0.97% (0.7470-1.1925%); Figure 2A and Table 5). Compared to those with stable eGFR (eGFR change 
of 0%), the adjusted HR of all-cause mortality was higher with greater eGFR decline but was largely flat 
in the range of minimal decline (-10% change or less) or rise (Figure 2A). For example, the adjusted HR 
was 1.8 (95% CI: 1.76-1.9) for -30% change, 2.3 (2.1-2.5) for -40% change, and 3.7 (3.2-4.4) for a -57% 
change. In terms of %PAR, a higher prevalence of smaller changes in eGFR surpassed the corresponding 
lower relative risk, with a peak of %PAR around -30 to -20% change (Figure 2A). Largely similar 
associations were observed among individuals with higher baseline eGFR, but a higher risk associated 
with a rise in eGFR (positive change in eGFR) was evident (Figure 2B). Of note, the prevalence of decline 
in eGFR was consistently less in those with higher baseline eGFR, and a -57% change in eGFR was very 
rare (~0.2%). A 30% decline in eGFR was consistently associated with higher subsequent all-cause 
mortality risk across cohorts for both lower and higher baseline eGFR (eFigure 16), although the 
absolute mortality risk varied markedly across cohorts even after accounting for covariates (eFigures 17 
and 18).  We observed consistent results for cardiovascular mortality and non-cardiovascular mortality 
(eFigures 19 and 20). 
 
With the larger eGFR declines, absolute all-cause mortality risk was consistently higher for all the levels 
of baseline eGFR across different subsequent follow-up time (Table 6 and eTables 4-5). For a baseline 
eGFR of 35 ml/min/1.73m2, the absolute all-cause mortality in 10 years was 32% if eGFR was stable, 
whereas the mortality risk was 50% for an eGFR change of -30%, 60% for -40% change, and 77% for -57% 
change. Similar patterns were observed for the CVD and non-CVD mortality risk (eTables 6 and 7). 
 
Further adjustment for smoking and albuminuria, when available, did not alter the results substantially 
(eFigures 21 and 22). Consistent results, greater mortality risk at a greater percent decline in eGFR, were 
observed for analyses using baseline period of 1-year or 3-year (eFigures 23-28 and Table 5). Results 
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were similar for the analysis using the 2-year slope of change in eGFR, although as anticipated, a given 
absolute decline in eGFR contributed to higher relative risk among those with lower vs. higher baseline 
eGFR (eFigures 29-31).   
 
Discussion 
In this international consortium meta-analysis of more than 1.7 million participants with 12,344 ESRD 
events and 223,922 deaths, we documented that smaller reductions in eGFR from baseline than 
doubling of serum creatinine were very strongly and consistently associated with subsequent risk of 
ESRD and captured a much higher proportion of the subsequent ESRD risk, providing a basis for their use 
as alternative outcomes for CKD progression.  The HR of ESRD adjusted for first eGFR and other 
covariates was exponentially higher with greater declines in eGFR across a wide range of cohorts, GFR 
levels, and other patient characteristics. eGFR changes of 57% and 30% were associated with greater 
than 30 and 5-fold adjusted HRs of ESRD, respectively, but the prevalence of the latter was nearly 
tenfold higher than the former and consequently had a much higher %PAR (44% vs. 10%). Although 
weaker than ESRD risk, associations with mortality were qualitatively similar. These data provide a basis 
for understanding the trade-off between higher risk and lower prevalence in choosing a larger or smaller 
percent change in eGFR as an outcome when studying CKD progression. While HRs were consistent 
across studies, absolute risks varied dramatically by baseline eGFR, participant characteristics and 
different cohorts, but were substantially higher than the life-time risk for comparably aged unselected 
populations.21   
 
Doubling of serum creatinine has been accepted by the Food and Drug Administration as a surrogate 
endpoint for CKD progression in clinical trials since 1993.3 Adoption of lesser eGFR decline as an 
alternative endpoint for CKD progression has the potential to shorten duration of follow up, reduce 
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costs and increase efficiency of clinical trials.  Consistency of effects over time suggests applicability for 
shorter as well as for longer trials, which is relevant for diseases that are progressing more rapidly or 
slowly, respectively.  The strong and consistent ESRD risk associations that we demonstrated here are a 
necessary, but not sufficient condition for a surrogate endpoint in clinical trials.  Several other types of 
data are useful, and preliminary results support our suggestion of a 30% to 40% change in eGFR as an 
outcome for clinical trials in CKD.22-24 First, evaluation of outcomes other than ESRD, such as 
cardiovascular disease and death, is important since they often occur more frequently and may precede 
ESRD. Our analyses show a 50% mortality risk in 10 years with 30% change in eGFR compared to 32% 
with stable eGFR and similar demographic and clinical characteristics, if baseline eGFR is 35 
ml/min/1.73m2. Second, evaluation of clinical trials is necessary to assess whether the effect of the 
treatment on the surrogate is consistently associated with the effect of treatment on the clinical 
endpoint. Attenuation of the hazard ratio of the treatment effect for lesser eGFR declines compared to 
the hazard ratio for the clinical endpoint can outweigh the benefit of an increased number of endpoint 
events. 11,22 Third, since the number and type of trials in CKD are limited, particularly with respect to 
length of follow-up and number of ESRD events reached, simulation studies are necessary to assess a 
wide range of potential scenarios to evaluate the utility, robustness and power of lesser eGFR declines.23 
In particular, simulation studies can address the impact of short-term (acute) effects on kidney function 
in the same or opposite direction from the long term (chronic) effect of a treatment, such as lower 
blood pressure or renin-angiotensin system inhibition. In principle, acute treatment effects on eGFR will 
be more important for endpoints defined by a smaller percent declines in eGFR.  An understanding of 
acute treatment effects on eGFR should be a part of any clinical trial which relies on an eGFR change as 
an alternative to ESRD. Difficulty in ruling out small acute treatment effects provide a rationale for 
favoring a larger decline in clinical trials (e.g. 30% or 40% change) than in observational studies and 
clinical practice where guidelines define a certain drop in eGFR as a drop in GFR category accompanied 
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by a 25% or greater drop in eGFR from baseline.7 Finally, absolute risk of ESRD is important to consider.  
Our results indicate that eGFR decline starting at severely reduced eGFR is associated with very high 
rates of ESRD during the subsequent 1-5 years. However, eGFR decline starting at moderately reduced 
or normal eGFR is associated with a markedly lower risk with ESRD occurring after 10 or more years. 
There is also marked variation across studies suggesting caution in the translation of the level of eGFR 
decline to exact risk of ESRD. 
 
To our knowledge, only one study investigated the association of eGFR change with ESRD risk,6 but our 
results regarding change in kidney function and mortality risk are consistent with several previous 
reports.8-10,25-28 Most of them investigated annualized rate of change,9,26-28 but a few reported that ≥~20-
25% decline in eGFR over 1-3 years conferred mortality risk.8,10,25 A time to event endpoint based on 
percent change in eGFR calculated from only two measurements of serum creatinine at baseline and 
follow-up is simpler and easier to implement in clinical trials than an end point defined on the rate of 
decline in eGFR. Similarly, percent change may be used as a clinical outcome in cohort studies and/or 
clinical care. Nevertheless, we comprehensively studied both percent and absolute change of eGFR over 
three different baseline periods and adjusted for baseline eGFR and covariates uniformly across cohorts. 
The consistent results across a wide range of cohorts in various settings/regions support the 
generalizability of our findings.  
 
As previously reported,25,27,29,30 we observed an increase in mortality risk with a rise in eGFR, particularly 
among individuals with higher first eGFR. We expanded the previous literature to include cause-specific 
death (CVD vs. non-CVD) and confirmed a similar relationship for both outcomes. This association may 
be a consequence of loss of muscle mass associated with chronic illness resulting in a decline in 
creatinine generation.28,31 It may also be a consequence of acute illness associated with resolving acute 
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kidney injury. The role of hyperfiltration in poor prognosis among those with higher eGFR is yet to be 
elucidated.32  
 
Despite its large size, broad scope and robustness of the findings across a large number of sensitivity 
analyses, this study has a number of limitations. Standardization of serum creatinine values may have 
varied across time and studies. Percent change in eGFR based on a single first and single last eGFR is less 
precise than alternative designs where multiple measures are available at each time point. Variation in 
design across cohorts introduces heterogeneity, but consistency across cohorts despite dramatic 
variation in design and populations increases our confidence in the results.   
 
Adjustment for the first eGFR means that the groups being compared have already diverged markedly at 
the end of the baseline period when follow-up for ESRD begins. For example, at a first eGFR of 30 
ml/min/1.73m2, percent changes of 57%,30% and 0% over a 2-year baseline correspond to a last eGFR 
during this period of 13, 21 and 30 ml/min/1.73m2, which provides insight to why greater eGFR declines 
are associated with greater subsequent ESRD and mortality risk. However, it also points out the 
distinction from clinical practice in which the last eGFR is known and the question of interest is often 
different -- whether previous progression adds information about risk above and beyond the last 
measurement.8,30  For clinical practice, the present analysis is useful for defining what level of change in 
the future can be considered important and what its consequences would be. However, once the 
change has occurred, the relative importance of the change vs. the last eGFR measure requires further 
analysis, and is beyond the scope of this paper. 
 
Conclusions 
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This meta-analysis of a wide range of cohorts with a large number of ESRD events confirms the validity 
of doubling of serum creatinine, which corresponds to a 57% decline in eGFR and is associated with a 
greater than 30-fold higher risk of ESRD, as an endpoint for CKD progression. However, over a one to 
three year period, a doubling of serum creatinine was rare in most studies.  A 30% decline in eGFR was 
approximately ten times more common and was associated with an approximately 5-fold increased risk 
of ESRD after adjustment for covariates including the first eGFR, providing an opportunity to define an 
alternative kidney endpoint for clinical trials, observational studies and clinical practice, with greater 
power over shorter periods of follow-up.   
 
 
18 
 
Figure legends 
Figure 1. Adjusted hazard ratio of end-stage renal disease associated with percent change in eGFR 
during a 2-year baseline period in eGFR<60 ml/min/1.73m2 (A) and eGFR≥60 ml/min/1.73m2 (B) and a 
histogram of the percent change in eGFR as well as approximate percent population attributable risk of 
end-stage renal disease.  Values trimmed at <-70% change (0.22% and 0.055% of the study population in 
eGFR <60 and ≥60 ml/min/1.73m2, respectively) and >40% change (5.9% and 0.51% of the population in 
eGFR <60 and ≥60 ml/min/1.73m2, respectively). 
 
Figure 2. Adjusted hazard ratio of all-cause mortality by percent change in eGFR, its distribution, and 
corresponding percent population attributable risk during a 2-year baseline period in eGFR<60 
ml/min/1.73m2 (A) and eGFR≥60 ml/min/1.73m2 (B). Values trimmed at <-70% change (0.30% and 
0.050% of the study population in eGFR <60 and ≥60 ml/min/1.73m2, respectively) and >40% change 
(5.8% and 0.46% of the population in eGFR <60 and ≥60 ml/min/1.73m2, respectively). 
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Table 1. Participating cohorts by baseline eGFR 
   End-stage renal disease All-cause mortality 
  
Participants 
N 
Serum 
creatinine, 
Median 
(IQR) 
 Events  
(n) 
Follow-
up  
Mean 
(SD), 
years 
Events 
(n) 
Follow-
up  
Mean 
(SD), 
years 
  
Baseline eGFR 
<60 
ml/min/1.73m2 
Baseline eGFR 
60+ 
ml/min/1.73m2   
Baseline eGFR 
<60 
ml/min/1.73m2 
Baseline eGFR 
60+ 
ml/min/1.73m2 
  
Baseline eGFR 
<60 
ml/min/1.73m2 
Baseline eGFR 
60+ 
ml/min/1.73m2   
Meta-Analysis                   
Baseline, 1-y 
 
466,068 
(458,965)* 
1,291,818 
(1,071,683)* 2 (2-3) 11,214 1,130 
3.1 
(2.3) 
144,558 
 
79,386 
 
4.4 
(3.6) 
Baseline, 2-y 
 
363,143 
(356,813)* 
1,226,114 
(984,380)* 3 (3-5) 7,523 1,009 
2.4 
(2.2) 
97,795 
 
60,808 
 
3.7 
(3.6) 
Baseline, 3-y 
 
235,560 
(230,178)* 
1,023,917 
(850,096)* 5 (4-5)  4,058 1,101 
2.0 
(2.9) 
55,135 
 
47,356 
 
3.2 
(4.0) 
Participating cohorts’ data for the 2 year baseline period 
AASK 744 169 7 (6-7) 243 8 6 (3) 112 24 6 (3) 
ADVANCE 1,542 8,457 4 (4-4) 16 21 3 (0.5) 150 407 3 (0.5) 
Aichi 14 1,798 2 (2-3)      1 15 7 (2) 
AKDN 35,617 257,597 3 (3-4) 206 63 2 (1) 3,878 5,779 2 (1) 
ARIC n/a n/a n/a n/a n/a n/a n/a n/a n/a 
BC CKD 7,986 656 10 (8-14) 1,178 53 2 (1) 1,730 67 3 (1) 
CARE 580 3,101 3 (3-3)      62 150 3 (1) 
CCF 17,102 31 6 (4-9) 290 1 1 (1) 1,746 3 1 (1) 
CHS n/a n/a n/a n/a n/a n/a n/a n/a n/a 
CIRCS 175 4,286 3 (2-3)      53 564 17 (4) 
CRIB 189 1 2 (2-2) 63 0 4 (2) 45 0 5 (2) 
Framingham 46 652 2 (2-2)      17 54 6 (1) 
Geisinger 14,850 20 6 (4-9) 257 0 3 (2) 2,287 4 3 (2) 
GLOMMS 1 645 2 11 (7-20) 58 0 3 (1) 274 1 3 (1) 
IPHS 2,147 60,319 3 (3-3)      983 10,019 12 (3) 
KP Hawaii 5,468 15,140 5 (4-8) 134 19 1 (0.7) 364 329 1 (1) 
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KPNW 320 202 7 (4-12) 21 10 4 (2) 167 73 5 (2) 
KSHS 217 62,810 3 (3-5)      5 169 3 (1) 
Maccabi 27,616 577,024 8 (7-9) 724 177 3 (1) 6,199 14,042 4 (1) 
MASTERPLAN 513 66 8 (7-9) 111 3 4 (1) 79 4 4 (1) 
MDRD 591 27 8 (7-8) 431 13 7 (5) 270 5 13 (4) 
MESA n/a n/a n/a     n/a n/a n/a 
MRFIT 185 11,342 3 (3-3) 30 239 21 (6) 86 3,900 23 (8) 
NephroTest 465 88 3 (2-3) 92 3 3 (2) 61 1 4 (2) 
NZDCS 1,913 7,093 3 (3-5) 152 100 6 (2) 728 1,081 6 (2) 
Ohasama 38 1,039 3 (3-3)      6 59 7 (1) 
Pima 12 1,594 2 (2-2) 6 101 12 (8) 10 343 13 (8) 
PREVEND 406 4,334 2 (2-2)      34 98 4 (1) 
Rancho Bernardo 33 174 2 (2-2)      9 17 7 (1) 
RENAAL 1,083 118 10 (9-10) 195 5 1 (1) 147 7 1 (1) 
Severance 140 6,105 2 (2, 3)      6 119 12 (2) 
Sunnybrook 1,484 1,173 7 (5-11) 168 18 3 (2) 437 90 5 (3) 
Taiwan MJ 2,247 96,533 2 (2-3)      362 1,676 7 (4) 
VA CKD 238,488 103,580 5 (4-7) 3,148 175 3 (1) 77,337 21,552 3 (1) 
ZODIAC 287 583 3 (3-3)       150 156 7 (3) 
n/a: Not available for 2y baseline period but those studies are included in other baseline periods. eGFR: estimated glomerular filtration rate. IQR: 
interquartile range. SD: standard deviation. 
Blank cells indicate the cohort did not have data on end-stage renal disease. Total numbers for cohorts with both end-stage renal disease and all-
cause mortality as outcomes use data from the end-stage renal disease analysis. 
*Total number for end-stage renal disease analyses.
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Table 2. Baseline characteristics for participating cohorts in the 2-y baseline period analysis 
  eGFR < 60 eGFR ≥60 
Cohort Age 
% 
Female 
% 
Black 
Baseline 
eGFR 
Total 
Chol SBP 
% 
DM 
%  
CVD 
% 
Alb 
% 
Smoke Age 
% 
Female 
% 
Black 
Baseline 
eGFR 
Total 
Chol SBP 
% 
DM 
%  
CVD 
% 
Alb 
% 
Smoke 
AASK 54 (11) 39 100 42 (11) 5 (1) 150 (24) 0 53 64 44 55 (10) 38 100 67 (6) 5 (1) 150 (24) 0 45 38 41 
ADVANCE 69 (6) 54 0 51 (8) 5 (1) 147 (23) 100 31 39 9 66 (6) 40 0 83 (13) 5 (1) 144 (21) 100 24 28 16 
Aichi n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 49 (6) 18 0 92 (14) 5 (1) 126 (15) 0.3 0.06 4.2 31 
AKDN 73 (11) 60 0 48 (10) n/a n/a 18 17 12 n/a 54 (15) 59 0 89 (16) n/a n/a 7 4 4 n/a 
BC CKD 70 (13) 46 0 33 (10) 5 (1) 134 (22) 42 4 69 6 56 (15) 45 1 78 (16) 5 (2) 136 (23) 52 1 67 6 
CARE 66 (7) 21 2 52 (7) 5 (0) 134 (20) 18 100 19 8 58 (9) 12 3 80 (13) 5 (0) 128 (18) 13 100 11 17 
CCF 72 (11) 55 12 47 (10) 5 (1) 131 (19) 26 22 27 8 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
CIRCS 63 (6) 70 0 54 (6) 5 (1) 135 (19) 6 4 7 14 54 (9) 66 0 84 (12) 5 (1) 130 (17) 5 1 2 23 
CRIB 61 (15) 34 6 28 (9) 6 (1) 150 (23) 16 44 81 12 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
Framingham 70 (6) 52 0 51 (8) 5 (1) 139 (16) 20 13 n/a 13 59 (9) 50 0 89 (18) 5 (1) 127 (18) 9 5 12 15 
Geisinger 70 (10) 59 1 52 (8) 5 (1) 131 (19) 31 15 44 7 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
GLOMMS 1 70 (13) 50 0 33 (7) n/a n/a 61 48 72 11 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
IPHS 70 (6) 68 0 54 (6) 5 (1) 139 (17) 9 16 9 9 59 (10) 68 0 87 (12) 5 (1) 133 (18) 5 5 2 7 
KP Hawaii 71 (11) 53 0 47 (10) 5 (1) 137 (22) 52 35 66 7 58 (13) 49 0 86 (16) 5 (1) 135 (20) 67 16 41 13 
KPNW 71 (10) 48 2 47 (11) n/a 142 (23) 405 240 8 13 67 (10) 55 5 73 (10) n/a 142 (22) 463 20 11 11 
KSHS n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 37 (7) 34 0 91 (11) 5 (1) 114 (14) 2 1 1 30 
Maccabi 72 (11) 58 0 50 (9) 5 (1) 134 (19) 30 9 40 1 47 (15) 59 0 94 (19) 5 (1) 124 (17) 11 1 17 2 
MASTERPLAN 61 (12) 31 0 36 (11) 5 (1) 136 (20) 24 30 37 21 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
MDRD 52 (12) 38 7 35 (11) 6 (1) 132 (18) 4 13 83 10 47 (12) 63 11 65 (4) 6 (1) 129 (20) 7 7 n/a n/a 
MRFIT 52 (5) 0 5 55 (5) 6 (1) 130 (17) 10 3 13 34 47 (6) 0 7 89 (13) 6 (1) 128 (14) 5 1 3 58 
NephroTest 60 (14) 32 10 37 (12) 5 (1) 137 (20) 24 19 96 15 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
NZDCS 71 (9) 57 0 48 (10) 5 (1) 142 (21) 100 2 14 8 59 (13) 49 0 86 (16) 5 (1) 138 (19) 100 1 7 16 
Ohasama n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 63 (8) 67 0 84 (11) 5 (1) 129 (17) 8 2 5 16 
Pima n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 32 (14) 63 0 122 (15) 4 (1) 118 (17) 27 n/a 18 28 
PREVEND 67 (9) 53 0 53 (7) 5 (1) 137 (21) 16 16 27 22 52 (11) 49 1 83 (13) 5 (1) 125 (18) 8 5 8 32 
Rancho Bernardo n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 69 (5) 52 0 78 (11) 5 (1) 132 (17) 16 10 8 8 
RENAAL 61 (7) 38 13 40 (11) 6 (1) 152 (19) 100 44 100 18 n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 
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Severance n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 44 (9) 38 0 90 (15) 5 (1) 120 (18) 1 0.4 4 32 
Sunnybrook 69 (14) 40 0 38 (12) n/a n/a 37 48 81 5 52 (16) 46 0 91 (20) n/a n/a 26 23 79 5 
Taiwan 63 (10) 40 0 52 (8) 5 (1) 139 (24) 9 9 12 21 40 (12) 50 0 96 (15) 5 (1) 119 (18) 2 2 1 22 
VA CKD 75 (9) 3 8 48 (9) 4 (1) n/a 43 45 41 n/a 69 (10) 3 11 71 (13) 4 (1) n/a 52 38 72 n/a 
ZODIAC 74 (8) 72 0 50 (8) 6 (1) 159 (24) 100 43 43 13 64 (11) 49 0 77 (12) 6 (1) 155 (25) 100 28 32 23 
Total 74 (10) 20 7 48 (10) 4 (1) 135 (20) 38 35 38 6 51 (16) 51 1 92 (18) 5 (1) 125 (18) 14 6 17 8 
Mean (SD).  n/a: Not available for relevant baseline period but included in other baseline period(s).eGFR: estimated glomerular filtration rate. 
Chol: cholesterol. SBP: systolic blood pressure. DM: diabetes mellitus. CVD: history of cardiovascular disease. Alb: albuminuria, proportion of 
participants with urine albumin-to-creatinine ratio ≥30 mg/g or urine protein-to-creatinine ratio ≥50 mg/g or dipstick protein ≥1+.  Smoke: 
current cigarette smoking. 
Appendices 1 and 2 provide further information regarding each cohort. 
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Table 3. Prevalence and adjusted hazard ratio of end-stage renal disease associated with percent decline in eGFR during baseline periods of one 
to three years duration by level of kidney function 
  Percent decline in eGFR during the 2-year baseline period 
  -57% -40% -30% -25% -20% 0% (Stable) 
eGFR<60 
ml/min/ 
1.73m2 
       
Baseline, 1-y Adjusted HR  21.5 (16.1, 28.8) 7.4 (6.1, 8.9) 4.0 (3.54, 4.6) 3.0 (2.76, 3.54) 2.4 (2.2, 2.7) ref 
 Cumulative Prevalence, % 0.43 (0.4130, 
0.4557) 1.7 (1.64, 1.79) 
4.2 (4.23.9, 
4.36) 
6.4 (6.41, 
6.58) 10 (10, 11) 54 (54, 55) 
 Cumulative PAR, % 4.3 (4.2, 4.3) 15 (14, 15) 25 (24, 25) 30 (29, 31) 35 (3433, 36) 46 (43, 48) 
Baseline, 2-y Adjusted HR  32.1 (22.3, 46.3) 10.3 2 (8.32, 12.87) 5.4 (4.65, 6.4) 4.0 (3.3, 4.8) 2.9 (2.5, 3.3) ref 
 Cumulative Prevalence, % 0.79 (0.7652, 
0.821.06) 
3.2 (3.22.8, 
3.37) 
6.9 (6.84, 
6.97.4) 10 (10, 1011) 
15 (1514, 
15) 54 (53, 54) 
 Cumulative PAR, % 10 (10, 10) 31 (31, 32) 44 (43, 45) 51 (49, 52) 55 (54, 57) 63 (60, 65) 
Baseline, 3-y Adjusted HR  36.8 (27.3, 49.7) 10.4 (8.0, 13.4) 5.0 (3.9, 6.4) 3.2 (2.4, 4.2) 2.5 (2.1, 3.1) ref 
 Cumulative Prevalence, % 1.3 (1.30.9, 1.47) 4.8 (4.73, 4.95.4) 
9.5 (9.48.9, 
9.610.2) 13 (13, 1314) 18 (18, 19) 
53 (5352, 
54) 
 Cumulative PAR, % 17 (17, 17) 40 (40, 41) 52 (51, 53) 56 (55, 57) 60 (58, 61) 65 (62, 67) 
eGFR≥60 
ml/min/ 
1.73m2 
 
      
Baseline, 1-y Adjusted HR  45.848.4 
(17.919.0, 
117.5123.0) 
13.0 1 (7.9, 
21.56) 
5.6 5 (3.76, 
8.54) 
3.8 7 (2.5, 
5.65) 
2.5 (1.98, 
3.43) ref 
 Cumulative Prevalence, % 0.13 (0.0513, 
0.1421) 
0.56 (0.5442, 
0.5770) 
1.8 (1.86, 
1.82.0) 
3.4 (3.42, 
3.57) 
6.8 (6.75, 
6.87.0) 64 (63, 64) 
 Cumulative PAR, % 4.9 (4.7, 4.9) 13 (12, 13) 20 (19, 21) 25 (23, 26) 30 (27, 31) 37 (3231, 42) 
Baseline, 2-y Adjusted HR  57.2 (21.9, 149.1) 15.3 (8.5, 27.2) 6.7 (3.9, 11.5) 4.6 (2.8, 7.6) 2.7 (1.8, 4.1) ref 
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 Cumulative Prevalence, % 
0.18 (0.07, 0.29) 0.85 (0.62, 1.09) 2.2 (2.0, 2.5) 4.0 (3.7, 4.3) 6.8 (6.5, 7.1) 
60 62 
(6062, 
6062) 
 Cumulative PAR, % 8.5 (8.4, 8.6) 21 (20, 21) 28 (27, 29) 32 (30, 34) 35 (33, 37) 41 (33, 47) 
Baseline, 3-y Adjusted HR  60.6 (19.0, 193.0) 15.7 (7.4, 33.4) 7.0 (3.9, 12.7) 4.6 (2.6, 7.9) 2.9 (2.0, 4.2) ref 
 Cumulative Prevalence, % 0.24 (0.0907, 
0.3841) 1.1 (0.8, 1.4) 2.7 (2.4, 3.0) 4.6 (4.3, 4.9) 8.5 (8.1, 8.8) 
64 67 
(6366, 
6467) 
 Cumulative PAR, % 6.3 (6.2, 6.3) 13 (13, 14) 20 (19, 21) 23 (22, 24) 27 (25, 29) 34 (28, 38) 
Cumulative indicates an eGFR decline of this level or greater. In parentheses are the 95% confidence intervals based on the whole eligible study 
sample in the Consortium as a standard population. 
eGFR: estimated glomerular filtration rate. HR: hazard ratio. PAR: population attributable risk.  
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Table 4. Risk of end-stage renal disease by percent decline in eGFR during a 2-year baseline period, first 
eGFR and subsequent follow-up time. 
First eGFR in 
the 2-year 
baseline 
period 
Follow-up 
time after the 
last eGFR 
Percent decline in eGFR during the 2-year baseline period 
57% 
decline 
40% 
decline 
30% 
decline 
25% 
decline 
20% 
decline Stable 
20 
1 year 63% 31% 19% 15% 1211% 3.9% 
3 year 97% 7372% 532% 4443% 3534% 13% 
5 year 100% 94% 8180% 7271% 6160% 26% 
10 year 100% 100% 99% 97% 9392% 57% 
35 
1year 20% 8.21% 4.98% 3.87% 2.87% 0.9695% 
3 year 5554% 2625% 16% 12% 9.2% 3.3% 
5 year 82% 4847% 3231% 25% 19% 7.10% 
10 year 99% 8483% 6564% 55% 4544% 18% 
50 
1 year 5.0% 1.9% 1.1% 0.986% 0.63% 0.23% 
3 year 16% 6.54% 3.8% 3.0% 2.2% 0.80% 
5 year 32% 14% 8.21% 6.4% 4.7% 1.7% 
10 year 66% 3433% 21% 17% 1312% 4.8% 
65 
1 year 0.71% 0.20% 0.090% 0.061% 0.04037% 0.014% 
3 year 3.9% 1.1% 0.49% 0.34% 0.21% 0.08079% 
5 year 12% 3.5% 1.6% 1.1% 0.768% 0.26% 
10 year 37% 12% 5.5% 3.9% 2.4% 0.90% 
80 
1 year 0.45% 0.12% 0.054% 0.04038% 0.023% 0.010090% 
3 year 2.5% 0.70% 0.31% 0.21% 0.13% 0.050% 
5 year 7.9% 2.2% 1.0% 0.769% 0.42% 0.16% 
10 year 25% 7.7% 3.4% 2.4% 1.5% 0.58% 
 
Colors indicating absolute risk gradient (based on percentiles of the cells in the table): 
100.0% 73.8% 444.23% 20.3% 12.0% 5.32% 3.21% 1.1% 0.62% 0.216% 0.01% 
 
Baseline risk is calculated for: 0% eGFR decline, eGFR 50 ml/min/1.73m2, age 60 y, male, non-black, 
systolic blood pressure 130, cholesterol 5 mmol/L, no diabetes, no history of cardiovascular disease.  
eGFR: estimated glomerular filtration rate.
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Table 5. Prevalence and adjusted hazard ratio of all-cause mortality associated with percent decline in eGFR during baseline periods of one to 
three years duration by level of kidney function 
  Percent decline in eGFR during the 2-year baseline period 
  -57% -40% -30% -25% -20% 0% (Stable) 
eGFR<60 
ml/min/ 
1.73m2 
       
Baseline, 1-y Adjusted HR  3.8 (3.3, 4.4) 2.4 (2.2, 2.6) 1.9 (1.7, 2.0) 1.6 (1.5, 1.8) 1.4 (1.4, 1.5) ref 
 Cumulative Prevalence, % 0.47 48 (0.34, 
0.6162) 1.8 (1.5, 2.0) 4.3 (4.0, 4.7) 6.5 (6.1, 6.9) 11 (10, 11) 54 (54, 55) 
 Cumulative PAR, % 0.48 (0.45, 0.50) 1.8 (1.7, 1.9) 3.7 (3.4, 3.9) 4.9 (4.5, 5.32) 
6.6 5 (6.05.9, 
7.1) 
9.9 8 (8.76, 
11) 
Baseline, 2-y Adjusted HR  3.7 (3.2, 4.4) 2.3 (2.1, 2.5) 1.8 (1.76, 1.9) 1.5 (1.4, 1.76) 1.4 (1.3, 1.4) ref 
 Cumulative Prevalence, % 0.97 (0.7470, 
1.1925) 3.5 (3.1, 3.9) 7.1 (6.6, 7.7) 11 (10, 11) 15 (14, 16) 
49 54 (4853, 
4955) 
 Cumulative PAR, % 0.96 (0.9089, 
1.01) 3.7 (3.4, 3.9) 
6.3 2 (5.8, 
6.76) 
8.07.9 (7.3, 
8.65) 
9.6 (8.87, 
10.4) 
12 (11, 
1314) 
Baseline, 3-y Adjusted HR  3.3 (2.7, 3.9) 2.2 (2.0, 2.4) 1.7 8 (1.6, 1.9) 1.5 (1.4, 1.7) 1.4 (1.3, 1.4) ref 
 Cumulative Prevalence, % 1.6 7 (1.3, 
1.92.1) 5.3 (4.87, 5.9) 10 (9, 11) 14 (13, 15) 19 (18, 20) 
51 54 (5053, 
5255) 
 Cumulative PAR, % 1.5 (1.4, 1.6) 5.1 (4.7, 5.5) 8.2 (7.5, 8.9) 10 (9, 11) 12 (11, 13) 14 (13, 16) 
eGFR≥60 
ml/min/ 
1.73m2 
 
      
Baseline, 1-y Adjusted HR  3.6 (2.65, 5.0) 2.1 (1.8, 2.5) 1.6 (1.4, 1.7) 1.3 (1.2, 1.4) 1.2 (1.1, 1.2) ref 
 Cumulative Prevalence, % 0.12 (0.04, 0.19) 0.48 (0.36, 0.6061) 1.6 (1.4, 1.8) 
3.1 (2.9, 
3.34) 6.5 (6.2, 6.8) 64 (64, 65) 
 Cumulative PAR, % 0.38 (0.33, 0.42) 1.4 (1.2, 1.6) 2.9 (2.5, 3.3) 3.8 7 (3.1, 4.3) 4.7 6 (3.8, 5.4) 4.8 (2.5, 6.9) 
Baseline, 2-y Adjusted HR  3.8 (2.8, 5.2) 2.4 (2.0, 2.9) 1.6 (1.4, 1.8) 1.3 (1.2, 1.5) 1.2 (1.1, 1.2) ref 
 Cumulative Prevalence, % 0.16 (0.06, 
0.2526) 0.73 (0.51, 0.94) 2.0 (1.7, 2.2) 3.7 (3.4, 4.0) 6.7 (6.4, 7.0) 
58 64 (5763, 
5864) 
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 Cumulative PAR, % 0.63 (0.56, 0.68) 2.6 (2.2, 2.8) 4.5 (3.8, 5.0) 5.6 7 (4.6, 6.5) 6.4 (5.1, 7.5) 5.3 (2.0, 8.3) 
Baseline, 3-y Adjusted HR  4.8 (3.7, 6.1) 2.3 (2.0, 2.6) 1.5 (1.3, 1.6) 1.2 (1.1, 1.3) 1.1 (1.1, 1.1) ref 
 Cumulative Prevalence, % 0.21 22 (0.0806, 
0.3438) 0.98 (0.71, 1.26) 
2.5 6 (2.23, 
2.89) 4.7 (4.3, 5.0) 8.8 (8.4, 9.2) 
60 68 (6067, 
6168) 
 Cumulative PAR, % 0.89 (0.83, 0.93) 3.3 (3.0, 3.5) 5.1 (4.5, 5.6) 6.0 (5.0, 6.8) 6.7 (5.4, 7.8) 5.7 (2.0, 9.1) 
Cumulative indicates an eGFR decline of this level or greater. In parentheses are the 95% confidence intervals based on the whole eligible study 
sample in the Consortium as a standard population. 
eGFR: estimated glomerular filtration rate. HR: hazard ratio. PAR: population attributable risk.  
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Table 6. Risk of all-cause mortality by percent decline in eGFR during a 2-year baseline period, first eGFR 
and subsequent follow-up time. 
First eGFR in 
the 2-year 
baseline 
period 
Follow-up 
time after 
the last 
eGFR 
Percent decline in eGFR during the 2-year baseline period 
57% 
decline 
40% 
decline 
30% 
decline 
25% 
decline 
20% 
decline Stable 
20 
1 year 11% 7.06.9% 5.3% 4.6% 4.10% 3.0% 
3 year 31% 21% 16% 14% 132% 9.4% 
5 year 52% 37% 29% 26% 23% 1817% 
10 year 8887% 7372% 62% 57% 52% 42% 
35 
1year 7.98% 5.04.9% 3.8% 3.3% 2.9% 2.21% 
3 year 23% 15% 12% 10% 9% 6.8% 
5 year 4140% 2827% 22% 19% 17% 13% 
10 year 77% 60% 50% 45% 41% 32% 
50 
1 year 5.76% 3.65% 2.7% 2.4% 2.1% 1.5% 
3 year 17% 11% 8.65% 7.5% 6.76% 4.9% 
5 year 31% 20% 16% 14% 13% 9.4% 
10 year 6564% 4847% 39% 35% 32% 24% 
65 
1 year 2.3% 1.4% 1.0% 0.78% 0.70% 0.60% 
3 year 7.9% 5.0% 3.4% 2.8% 2.5% 2.1% 
5 year 15% 10% 6.4% 5.3% 4.8% 4.1% 
10 year 37% 25% 18% 15% 13% 11% 
80 
1 year 2.5% 1.6% 1.1% 0.86% 0.77% 0.66% 
3 year 8.7% 5.5% 3.7% 3.0% 2.7% 2.4% 
5 year 16% 10% 7.1% 5.8% 5.2% 4.5% 
10 year 40% 28% 19% 16% 15% 13% 
 
Colors indicating absolute risk gradient (based on percentiles of the cells in the table): 
878% 42% 3029% 19% 15% 11% 7.0% 54.9% 3.0% 2.1% 10.6% 
 
Baseline risk is calculated for: 0% eGFR decline, eGFR 50 ml/min/1.73m2, age 60 y, male, non-black, 
systolic blood pressure 130, cholesterol 5 mmol/L, no diabetes, no history of cardiovascular disease.  
eGFR: estimated glomerular filtration rate.  
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Figure 2 
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